Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30409049 | 1.00 | NR1H2 (0.67) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL30409090 | 0.95 | ESR2 (0.69) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL3009208 | 0.95 | ESR2 (0.69) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL24215797 | 0.90 | ESR2 (0.53) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL29586616 | 0.88 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL2416879 | 0.88 | NR1H2 (0.67) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL24676283 | 0.83 | NR1H2 (0.62) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL4590083 | 0.83 | NR1H2 (0.62) | NR1H2ESR2MAPK1NPC1RAB9A | |
| SCHEMBL30548176 | 0.82 | ESR2 (0.69) | NR1H2ESR2MAPK1HDAC1DDB1 | |
| SCHEMBL451998 | 0.82 | ESR2 (0.69) | NR1H2ESR2MAPK1HDAC1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | EVRYS BIO, LLC (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022013728-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2022-01-20 | — | — | WO | disclosed |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | EVRYS BIO, LLC (US) | 2021-05-13 | — | — | US | disclosed |
| WO-2019079519-A1 | BROAD SPECTRUM ANTIVIRAL COMPOSITIONS AND METHODS | FORGE LIFE SCIENCE, LLC (US) | 2019-04-25 | — | — | WO | disclosed |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | SUNESIS PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459321-B2 | Broad spectrum antiviral compositions and methods | IRF3, MAVS, ZC3HAV1 | NR1H2 1472/4885ESR2 3487/4885MAPK1 3394/4885 |
| US-20080200454-A1 | CARBON-LINKED TETRAHYDRO-PYRAZOLO-PYRIDINE MODULATORS OF CATHEPSIN S | CTSS, CTSK, CTSZ | NR1H2 728/4885ESR2 1521/4885MAPK1 1807/4885 |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | NR1H2 407/4885ESR2 3660/4885MAPK1 2358/4885 |
| US-20210139475-A1 | Broad Spectrum Antiviral Compositions and Methods | MAVS, IRF3, ZC3HAV1 | NR1H2 1583/4885ESR2 3095/4885MAPK1 3858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.